Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier.
Shaw
J M
JM
Alcon Laboratories, Fort Worth, Texas.
Shaw
K V
KV
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000327:Adsorption; D001053:Apolipoproteins / Q000494:pharmacology; D001057:Apolipoproteins E / Q000378:metabolism; D001692:Biological Transport; D002478:Cells, Cultured; D003630:Daunorubicin / Q000494:pharmacology; D004337:Drug Carriers / Q000008:administration & dosage / Q000494:pharmacology*; D015195:Drug Design; D006493:Heparin / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000494:pharmacology; D008074:Lipoproteins / Q000008:administration & dosage / Q000494:pharmacology*; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D008727:Methotrexate / Q000031:analogs & derivatives* / Q000494:pharmacology; D010714:Phosphatidylethanolamines / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000378:metabolism
D001053:Apolipoproteins; D001057:Apolipoproteins E; D004337:Drug Carriers; D008055:Lipids; D008074:Lipoproteins; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D010714:Phosphatidylethanolamines; D011956:Receptors, Cell Surface; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C073403:5-hexadecyl methotrexate; D006493:Heparin; D008727:Methotrexate; D003630:Daunorubicin